Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 38.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,670,000 shares of the company's stock after buying an additional 465,000 shares during the period. Adage Capital Partners GP L.L.C. owned about 2.11% of Viridian Therapeutics worth $32,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of VRDN. R Squared Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter valued at about $26,000. AlphaQuest LLC boosted its holdings in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after purchasing an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after purchasing an additional 1,516 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $164,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $219,000.

Viridian Therapeutics Trading Up 0.2 %

Shares of Viridian Therapeutics stock traded up $0.03 on Monday, reaching $13.53. The company had a trading volume of 683,510 shares, compared to its average volume of 1,201,045. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a market cap of $1.10 billion, a PE ratio of -3.14 and a beta of 0.81. The firm's 50 day moving average price is $14.18 and its two-hundred day moving average price is $18.14. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on VRDN shares. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Needham & Company LLC reissued a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.